Poseida announced a strategic global collaboration agreement with Roche potentially worth up to $6 billion. See why I feel PSTX stock appears undervalued.
The progress of gene therapies continues to be stymied by safety risks associated with the viruses used to deliver them. Takeda Pharmaceutical is partnering with Poseida Therapeutics in a bet that the biotech’s non-viral technologies could offer a safer alternative.